The epidermal growth factor receptor is a member of the receptor tyrosine kinase family
whose members play a critical role in oncogenesis. In particular, EGFR has been shown to …

Background The use of biomarkers to target anti-EGFR treatments for metastatic colorectal
cancer (CRC) is well-established, requiring molecular analysis of primary or metastatic …

Introduction 3. The type I growth factor receptors and their ligands 3.1. Expression pattern
and prognostic significance of EGFR and its ligands in colorectal cancer 3.2. Expression …

Epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor,
which is overexpressed in many types of cancer. The use of EGFR-targeting monoclonal …

Purpose: Imaging techniques for highly specific detection of cancer cells in vivo can have
applications ranging from preclinical drug discovery studies to clinical cancer diagnosis and …

It takes on average 6–12 years to develop new anticancer drugs from discovery to approval.
Effective new agents prolong survival. To demonstrate the importance of rapid drug …

Due to the difficulty in sampling of metastatic tumors, patient selection is commonly based on
results of primary tumor samples when metastatic samples are not available. However, due …

Background High‐grade serous ovarian carcinoma (HGSOC), the most common histologic
subtype of ovarian epithelial cancer, is associated with treatment resistance, enhanced …

Background: Resection of colorectal cancer liver metastasis (CRCLM) with curative intent
has long-term benefit in∼ 40% of cases. Prognostic biomarkers are needed to improve …

Background Many studies have investigated the prognostic role of biomarkers in colorectal
liver metastases (CRLM). However, no biomarker has been established in routine clinical …